- Home
- RSF vs ATNM Comparison
RSF vs ATNM Comparison
Compare RSF & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSF
- ATNM
- Stock Information
- Founded
- RSF 2016
- ATNM 2000
- Country
- RSF United States
- ATNM United States
- Employees
- RSF N/A
- ATNM N/A
- Industry
- RSF Investment Managers
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- RSF Finance
- ATNM Health Care
- Exchange
- RSF Nasdaq
- ATNM Nasdaq
- Market Cap
- RSF 49.1M
- ATNM 51.5M
- IPO Year
- RSF N/A
- ATNM N/A
- Fundamental
- Price
- RSF $14.56
- ATNM $1.36
- Analyst Decision
- RSF
- ATNM Strong Buy
- Analyst Count
- RSF 0
- ATNM 3
- Target Price
- RSF N/A
- ATNM $4.67
- AVG Volume (30 Days)
- RSF 11.8K
- ATNM 508.7K
- Earning Date
- RSF 01-01-0001
- ATNM 08-04-2025
- Dividend Yield
- RSF 10.61%
- ATNM N/A
- EPS Growth
- RSF N/A
- ATNM N/A
- EPS
- RSF N/A
- ATNM N/A
- Revenue
- RSF N/A
- ATNM N/A
- Revenue This Year
- RSF N/A
- ATNM N/A
- Revenue Next Year
- RSF N/A
- ATNM N/A
- P/E Ratio
- RSF N/A
- ATNM N/A
- Revenue Growth
- RSF N/A
- ATNM N/A
- 52 Week Low
- RSF $14.81
- ATNM $1.03
- 52 Week High
- RSF $16.23
- ATNM $8.64
- Technical
- Relative Strength Index (RSI)
- RSF 33.94
- ATNM 43.05
- Support Level
- RSF $14.58
- ATNM $1.41
- Resistance Level
- RSF $14.73
- ATNM $1.95
- Average True Range (ATR)
- RSF 0.08
- ATNM 0.12
- MACD
- RSF -0.00
- ATNM -0.02
- Stochastic Oscillator
- RSF 8.00
- ATNM 11.93
About RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.